ReviewDrug discovery today2019
The influence of ketamine on drug discovery in depression.
Review in Drug discovery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.European child & adolescent psychiatry · 2021Pooled it
- Ketamine and Evolving Neuroplasticity.Clinical drug investigation · 2026Review
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Review
- Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.Brain and behavior · 2024Article
- Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors.Journal of neurochemistry · 2024Article
- Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression.Analytical and bioanalytical chemistry · 2024Review
- Microdosing ketamine inbioRxiv : the preprint server for biology · 2023Article
- Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.Neuronal signaling · 2023Review
- Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023Review
- Review
- Alterations in Astrocytic Regulation of Excitation and Inhibition by Stress Exposure and in Severe Psychopathology.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Review
- The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.European archives of psychiatry and clinical neuroscience · 2022Article
- Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants.Molecular neurobiology · 2022Review
- Review
- Imaging the effect of ketamine on synaptic density (SV2A) in the living brain.Molecular psychiatry · 2022Article
- BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.BMC psychiatry · 2022Article
- Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.Handbook of experimental pharmacology · 2022Review
- The Rapid and Long-Lasting Antidepressant Effects of Iridoid Fraction inFrontiers in pharmacology · 2022Article
- Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.Psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.